Cited by 99Vitamin C and Antioxidants ResearchComplementary and Alternative Medicine StudiesAntioxidant Activity and Oxidative Stress

Intravenous vitamin C in the supportive care of cancer patients: A review and rational approach

Open access
Klimant, E., Wright, H., Rubin, D., Seely, D., Markman, M.·2018·Current Oncology

Abstract

This article reviews intravenous vitamin C (IV C) in cancer care and offers a rational approach to enable medical oncologists and integrative practitioners to safely provide IV C combined with oral vitamin C to patients. The use of IV C is a safe supportive intervention to decrease inflammation in the patient and to improve symptoms related to antioxidant deficiency, disease processes, and side effects of standard cancer treatments. A proposed rationale, together with relevant clinical safety considerations for the application of IV C in oncologic supportive care, is provided.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3747/co.25.3790

Cites

83 of 83 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • A significant number of clinical trials have indicated that vitamin C administered intravenously in high-doses (in most trials, 50-100 g twice or thrice weekly) as a treatment for various cancers including glioblastoma, ovarian, prostate, lung, or rectum cancer is well tolerated with minimal toxicity, improves the quality of life for patients, and has a synergistic therapeutic effect when combined

    “A significant number of clinical trials have indicated that vitamin C administered intravenously in high-doses (in most trials, 50–100 g twice or thrice weekly) as a treatment for various cancers including glioblastoma, ovarian, prostate, lung, or rectum cancer is well tolerated with minimal toxicity, improves the quality of life for patients, and has a synergistic therapeutic effect when combined”

    From Vitamin C-Sources, Physiological Role, Kinetics, Deficiency, Use, Toxicity, and Determination (2021) · cites this paper as [184]

    Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

    Experimental — accuracy not yet measured
  • Most of these studies were not designed as large-scale randomized clinical trials and clear verifications of the clinical efficacy of vitamin C are currently rather limited.

    “However, most of these studies were not designed as large-scale randomized clinical trials and clear verifications of the clinical efficacy of vitamin C are currently rather limited [177,182,183,184].”
  • Many clinical studies report that intravenous high-dose ascorbate is well tolerated, improves quality of life, and when combined with radiation or standard chemotherapy has synergistic effects and fewer side effects.

    “a significant number of clinical studies to date have indicated that intravenous high-dose ascorbate is well tolerated in patients with minimal toxicity, improves the quality of life for patients and has demonstrated synergistic therapeutic effects as well as reduced side effects when combined with radiation and standard chemotherapies.”

    From Targeting cancer vulnerabilities with high-dose vitamin C (2019) · cites this paper as [99]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 12

  1. Fain O, Mathieu E, Thomas M. Scurvy in patients with cancer. BMJ 1998;316:1661-2.
  2. Bodansky O, Wroblewski F, Markardt B. Concentrations of ascorbic acid in plasma and white blood cells of patients with cancer and noncancerous chronic disease. Cancer 1952;5:678-84.
  3. Fain O. Vitamin C [French]. Rev Prat 2013;63:1091-6.
  4. Takahashi H, Mizuno H, Yanagisawa A. High-dose intrave- nous vitamin C improves quality of life in cancer patients. Personalized Medicine Universe 2012;1:49-53.
  5. Benke KK. Modeling ascorbic acid level in plasma and its depen- dence on absorbed dose. J Aust Coll Nutr Env Med 1999;18:11-12.
  6. Hickey DS, Roberts HJ, Cathcart RF. Dynamic flow: a new model for ascorbate. J Orthomol Med 2005;20:237-44.
  7. United States, Department of Health and Human Services, National Institutes of Health, National Center for Biotech- nology Information (ncbi). PubChem Compound Database: Ascorbic acid [Web resource (CID=54670067)]. Bethesda, MD: ncbi; n.d. [Available at: https://pubchem.ncbi.nlm.nih. gov/compound/54670067; cited 12 January 2016]
  8. Spellberg MA, Keeton RW. Excretion of ascorbic acid in relation to saturation and utilization with some diagnostic implications. Arch Intern Med 1939;63:1095-116.
  9. Mikirova NA, Jackson JA, Riordan NH. The effect of high dose IV vitamin C on plasma antioxidant capacity and level of oxidative stress in cancer patients and healthy subjects. J Orthomol Med 2007;22:153-60.
  10. Petroianu A, Alberti LR. Effect of oral supplementation of vitamin C on intestinal anastomotic resistance. Rev Col Bras Cir 2011;38:54-8.
  11. Braunstein EM. Glucose 6-phosphate dehydrogenase defi- ciency. In: Lichtin AE, ed. Merck Manual: Professional Edition. 19th online ed. Kenilworth, NJ: Merck Sharp and Dohme Corp; 2018. [Available at: http://www.merckmanuals.com/ professional/hematology_and_oncology/anemias_caused_ by_hemolysis/glucose-6-phosphate_dehydrogenase_g6pd_ deficiency.html; cited 8 January 2016]
  12. Fritz H, Flower G, Weeks L, et al. Intravenous vitamin C a nd ca ncer: a systemat ic rev iew. Integr Cancer Ther 2014;13:280-300.

Cited by

Sorted by citations

Authors
Klimant, E., Wright, H., Rubin, D., Seely, D., & Markman, M.
Affiliations
Cancer Treatment Centers of America (US)
Venue
Current Oncology
Publisher
MDPI AG
Published
2018-04-01
Volume
25
Issue
2
Pages
139-148
ISSN
  • 1198-0052 (ISSN-L)
  • 1718-7729
OpenAlex
W2800392143
Cited by
99
References
83
Citations by year
2026: 3 · 2025: 10 · 2024: 10 · 2023: 8 · 2022: 13 · 2021: 25 · 2020: 16 · 2019: 11 · 2018: 3
FWCI
1.76
Type
journal article
Language
en
Open access
Locations
  • Current Oncology (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Nursing › Nutrition and Dietetics › Vitamin C and Antioxidants Research
  • Health Sciences › Medicine › Complementary and alternative medicine › Complementary and Alternative Medicine Studies
  • Health Sciences › Medicine › Biochemistry › Antioxidant Activity and Oxidative Stress
Keywords
intravenous vitamin C, vitamin C, cancer supportive care, integrative oncology, antioxidant deficiency, inflammation, chemotherapy side effects, clinical safety
MeSH terms
Administration, Oral, Antioxidants, Ascorbic Acid, Humans, Neoplasms, Quality of Life, Vitamin D Deficiency, Oxidative Stress, Administration, Intravenous

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review